Skip to main
LUNG

Pulmonx (LUNG) Stock Forecast & Price Target

Pulmonx (LUNG) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 0%
Hold 43%
Sell 0%
Strong Sell 0%

Bulls say

Pulmonx Corp has strengthened its balance sheet through a new five-year interest-only credit facility, securing up to $60 million in committed capital and extending debt maturity to 2031. The company's Q3 2025 financial results showed a revenue increase of 5% year-over-year to $21.5 million, with international revenue growth outpacing the U.S. segment, alongside a maintained gross margin of 75%. Additionally, Pulmonx reported a full-year revenue growth to $90.5 million from $83.8 million in 2024, highlighting improved operational efficiency and a strategic focus on increasing the eligible patient pool through innovative treatment approaches.

Bears say

Pulmonx Corp reported modest annual revenue growth of 8%, totaling $90.5 million for the full year 2025, yet experienced a decline in fourth-quarter revenue to $22.6 million, primarily due to weakened performance in the U.S. market. The company's cash, cash equivalents, and marketable securities decreased by approximately $32 million year-over-year, totaling $69.8 million at year-end 2025, with expectations of an additional $23 million decline in cash throughout 2026 without further credit facility drawdowns. Furthermore, with operating expenses reaching $120.8 million and a net loss of $54.0 million, Pulmonx's financial stability remains a concern, indicating potential challenges in achieving sustainable growth.

Pulmonx (LUNG) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 0% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pulmonx (LUNG) Forecast

Analysts have given Pulmonx (LUNG) a Buy based on their latest research and market trends.

According to 7 analysts, Pulmonx (LUNG) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pulmonx (LUNG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.